Gastrointestinal RBD-1016, a GalNAc-siRNA therapy effective in hepatitis B models June 23, 2023 At the ongoing European Association for the Study of the Liver meeting, researchers from Suzhou Ribo Life Science Co. Ltd. presented preclinical data on RBD-1016 in two models of chronic hepatitis B virus (HBV) infection.Read More
